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ABSTRACT 
Background 
Fasting and energy restricting diets have a potential means of delaying or preventing the onset of a range 
of age-related metabolic and neoplastic diseases. Consistently at the centre of this effect appears to be a 
significant reduction in circulating IGF-1 levels. The aim of the current systematic review and meta-analysis 
was to determine the influence of fasting and energy restriction on IGF-1 levels in human subjects. 
Methods 
A comprehensive systematic search was conducted from onset of the database to February 2019 in Embase, 
MEDLINE/PubMed, and SCOPUS to identify randomized clinical trials that investigating the impact of 
fasting or energy restriction circulating IGF-1 levels. Effect size was reported as weighted mean difference 
(WMD) and 95% confidence intervals (CI) using a random-effects models. Subgroup analysis was 
performed to identify the probable source of heterogeneity among trials. 
Results 
Total pooling of fasting and energy restriction randomised controlled trials in WMD analysis revealed no 
significant effect on circulating IGF-1 levels (WMD: -16.41 ng/ml, 95% CI: -35.88, 3.07). Sub grouped 
analysis fasting regimens appeared to substantially reduce IGF-1 (WMD: -28.87 ng/ml, 95% CI: -43.69, -
14.05, I2=00%), energy restricting regimens failed to do the same (WMD: -10.98 ng/ml, 95% CI: -33.08, 
11.11, I2=90%). Within this final subgrouping, it was observed that only energy restriction regimens of 
50% or greater of normal daily energy intake were capable of significantly reducing IGF-1 levels (WMD: 
-36.57 ng/ml, 95% CI: -59.19, -13.95, I2=00%). Finally, a meta regression were noted in which the 
percentage restriction of daily energy intake inversely correlated with plasma IGF-1 levels (p=0.04).  
Conclusion 
This study uncovered that fasting significantly reduced levels of IGF-1, while energy restriction diets were 
successful only when intake was reduced by 50% or more.  
Keyword: Fasting; Energy restriction; IGF-1  
1. INTRODUCTION 
The growth hormone and insulin-like growth factor-1 (GH/IGF-1) axis is a well-conserved endocrine 
system that regulates organismal size as well as lifespan (Fontana et al., 2010). IGF-1 is an anabolic 
hormone mainly synthesized in the liver and locally expressed in peripheral tissues under the control of 
pituitary GH, within a negative feedback loop system (Sherlock and Toogood, 2007). GH/IGF-1 signalling 
is a requisite for normal growth in youth and for the maintenance of anabolic processes in adults (Sherlock 
and Toogood, 2007). IGF-1 bioactivity and bioavailability are purportedly influenced by six binding 
proteins (IGFBPs) (Lee et al., 1997). The most abundant binding protein in serum is IGFBP-3, which is a 
circulating IGF-1 reservoir with potential IGF-1-independent cell survival and proliferative effects 
(Franklin et al., 2003). During the process of aging there is a gradual decrement and alteration in the pattern 
and production of GH secretion and IGF-1, respectively. This phenomenon, coined ‘somatopause’ (Müller 
et al., 2012), is considered to contribute to a relative anabolic hormone deficiency in the elderly. The 
somatopause is associated with alterations in body composition and metabolism and is comparable to those 
observed in adults with GH deficiency. This primarily manifests as a reduction of bone and muscle mass 
and strength, increased fat mass, dyslipidaemia, arterial hypertension, cardiovascular diseases, and 
cognitive decline (De Marinis et al., 2002). The impaired activity of the GH/IGF-1 axis could, putatively, 
be the basis of the numerous metabolic, biochemical, and functional alterations that characterize aging and 
disease (Müller et al., 2012).  
Studies have reported that higher IGF-1 bioactivity may be correlated to an increased risk of several 
cancer types, including prostate (Renehan et al., 2004; Travis et al., 2016), colorectal (Kaaks et al., 2000), 
and premenopausal breast cancers (Sugumar et al., 2004). Given the potential opposing roles of the IGF-1 
axis on overall markers of health and co-morbidities, a concerted effort is required to better understand the 
determinants of IGF-1 bioactivity. To that end, contemporary work has focussed on the influence of dietary 
alterations, and in particular, over or under-consumption (i.e., fasting). Overconsumption of food is well 
known to manifest into metabolic comorbidities (e.g., insulin resistance, excessive accumulation of visceral 
fat, etc.), particularly when in combination with a sedentary lifestyle. Historically, animals, including 
humans, evolved in environments where food supply went through periods of relative scarcity. In turn, they 
developed numerous adaptations that permitted them to function, both physically and cognitively, when in 
a calorie deprived/fasted state. Intermittent fasting encompasses patterns of consumption in which 
individuals go extended periods of time (e.g., 16–48 h) with little or no energy intake, with intervening 
periods of normal food intake, on a recurring basis (Mattson et al., 2017). 
Studies of laboratory animals have elucidated the cellular and molecular mechanisms by which 
individuals respond to fasting can increase overall fitness, and resistance to injury and a plethora of diseases 
(Longo and Mattson, 2014). In laboratory rodents periodic and intermittent fasting has resulted in profound 
beneficial effects on health and, notably, can counteract disease onset and improve functional outcome in 
experimental models of a wide range of disorders including diabetes, cardiovascular disease, cancers and 
neurological disorders such as Alzheimer’s disease, dementia, Parkinson’s disease and stroke (Mattson et 
al., 2017).  
Given these promising results found in animal experimental models, the transferability of such 
findings into humans is of paramount interest. Recent randomized controlled trials in humans have 
demonstrated that intermittent fasting, including diets that mimic some aspects of fasting, are achievable 
and sustainable in humans, conferring numerous improvements of health indicators in healthy individuals, 
as well as some with chronic diseases. In studies administering intermittent fasting (e.g., 60% energy 
restriction on two days per week or every other day), periodic fasting (e.g., a five day diet providing 750–
1100 kilocalories (kcal)) or time-restricted feeding (limiting the daily period of food intake to 8 h or less) 
in normal and overweight human participants, efficacy for weight loss and improvements across multiple 
health indicators including insulin resistance and reductions in cardiovascular risk factors has repeatedly 
been shown (Hill et al., 1989). The cellular and molecular mechanisms by which fasting may improve 
health and attenuates disease processes appears to rely on activation of adaptive cellular stress response 
signalling pathways which augments mitochondrial health, DNA repair and autophagy. Moreover, fasting 
may also promote stem cell-based regeneration, as well as continuing metabolic effects (Mattson et al., 
2017). 
IGF-1 has strong relationships with cancer risk, aging, diabetes and innumerable other non-
communicable diseases (Hursting et al., 2012; Wei et al., 2016). Although mechanistically speculative, 
there may be scope for easily-administrable fasting or dietary restriction regimens to positively influence 
IGF-1 levels. Therefore, it is of importance that relevant findings to-date be compiled and assessed. We, 
therefore, sought to systematically review and meta-analyse the influence of fasting and energy restriction 
on IGF-1 levels in human subjects. 
 
2. METHODS 
2.1. Study design and search strategy 
This systematic review and meta-analysis was performed according to the PRISMA [Preferred Reporting 
Items for Systematic Review and Meta-analysis] Statements (Moher et al., 2015). A comprehensive 
systematic search was conducted in Embase, PubMed/MEDLINE, and SCOPUS by two independent 
reviewers (JR and HKV) from inception until February 2019. We considered randomized Control Trials 
(RCTs) that evaluating the effects of fasting or/and energy restriction on circulating IGF-1 levels. Search 
strategy details were reported in Supplementary Table 1. Search strategy was developed without using date 
or language restrictions.  
2.2. Selection criteria 
The participant, intervention, comparison, outcome, time, and study design (PICOTS) criteria was used to 
establish study inclusion criteria. Endnote Reference Manager X8© was used for citation management. 
Duplicates were excluded using the Endnote function “remove duplicates”. Two independent authors (JR 
and HKV) investigated the abstract of all articles to select eligible studies and they reviewed the full-texts 
of relevant articles too. The following inclusion criteria were used: 1. Studies that have randomized 
controlled trial (RCT) design; 2. Studies on adult patients (age>18 years); 3. Studies reporting results in the 
form of mean differences (MD) with the 95% confidence intervals (95% CI). Exclusion criteria were: 1. 
Studies not reporting IGF-1 levels before and after intervention; 2. Animal studies; 3. Non-randomised 
study designs; 4. Designs without a control group; 5. Conference abstracts, commentaries, case-reports, 
reviews. 
2.3. Data extraction 
One reviewer (JR) extracted the data, which was subsequently double checked by an additional reviewer 
(HKV). The data extracted included author, country, year of publication, duration of follow up, number of 
patients in intervention and control group, mean age (years), percent of energy restriction, and mean 
differences/standard deviation (SD) of IGF-1 levels in baseline study and post-intervention. 
2.4. Quality assessment 
Risk of bias assessment was applied to all included studies using the Cochrane collaboration’s tool for 
quality assessment of randomized control trials (Higgins et al., 2011), which contains the following 
domains: selection bias (random sequence generation), selection bias (allocation concealment), 
performance bias, detection bias, attrition bias, reporting bias and other sources of bias.  
2.5. Epidemiological cohort study 
In order to confirm the findings inof this meta-analysis study onof RCTs, we also examined the results of  
a population- based cohort study. The third national health and nutrition examination survey (NHANES 
III) data were used to investigate theion relationship between daily energy intake and IGF-1 (35, 36). In 
NHANES III study, daily energy intake and IGF-1 levels were evaluated viaby 24 hours recalls and ELISA, 
respectively. Participants whose total daily energy intake was outside of the credible range (men <800 or 
>4,200 kcal/day, women <600 or >3,500 kcal/day) were excluded too (37, 38). In the present study, wWe 
excluded participants  with missing data in age, gender, IGF-1 levels, or daily energy intake. Furthermore, 
participants with cancer or diabetes were excluded from analyseis.  
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2.6. Statistical analysis 
Weighted mean difference (WMD) with the 95% CI were used for examination of effects of fasting or 
energy restriction on circulating IGF-1 levels. When the standard error (SE) of the mean difference for 
studies was reported, we  calculated the SD using the following formula: SD2 baseline + SD2 final – (2 R* 
SD baseline + SD final) (Borenstein et al., 2009). Pooled WMD from included studies was calculated with 
derSimonian and Laird random-effects model. Heterogeneity across included studies was assessed using 
the Q-test, the I-squared and an alpha of 0.05 for statistical significance. Subgroup analysis was performed 
to identify the source of heterogeneity among trials. Type of intervention (fasting or energy restriction) and 
percent of energy restriction (less than 50% or more than 50% daily requirement energy intake) were 
considered as predefined source of heterogeneity. The potential effects of energy restriction were examined 
using fractional polynomial modelling in dose-response analysis and meta-regression analysis. The 
publication bias was determined using Egger’s, Begg’s tests and funnel plot. All statistical tests were 
conducted using the STATA 14 (StataCorp LP, College Station, USA), using a p value of 0.05 for statistical 
significance. One-way ANOVA was used to compare IGF-1 categories and daily energy intake(kcal/d) in 
men and women. 
 
3. RESULTS 
Primary systematic search identified 3190 studies from PubMed/MEDLINE, Scopus, and Embase 
(Supplementary Figure 1). Duplicate studies were removed and 1959 studies remained. During the primary 
screening, which was based on review of study titles and abstracts, 1925 studies were excluded and 34 
studies remained for full text extraction. During secondary screening, 24 studies were excluded for the 
following reasons: 1) non-RCT design (n=5), 2) and non-human trials (n=19). Ten studies (eleven arms) 
containing 497 participants were included in the quantitative meta-analysis (Barnosky et al., 2017; 
Brandhorst et al., 2015; Fontana et al., 2016; Fontana et al., 2008; Kessler et al., 2018; Koehler et al., 2016; 
Moro et al., 2016; Papageorgiou et al., 2017; Smith et al., 1995; Tam et al., 2014; Wei et al., 2017). One 
article from included studies had two arms, one arm for men and another arm for women(Papageorgiou et 
al., 2017). 
3.1. Study characteristics 
Characteristics of the included studies are detailed in Table 1. Six studies were conducted in US (Fontana 
et al., 2016; Fontana et al., 2008; Papageorgiou et al., 2017; Smith et al., 1995; Tam et al., 2014; Wei et al., 
2017), two in Germany (Kessler et al., 2018; Koehler et al., 2016), one in the UK (Papageorgiou et al., 
2017), and one in Italy (Moro et al., 2016). All studies were published between the years 1995 to 2018. 
Three studies investigated fasting effect (Kessler et al., 2018; Moro et al., 2016; Wei et al., 2017), while 
the remaining seven studies involved an energy restriction design (Barnosky et al., 2017; Fontana et al., 
2016; Fontana et al., 2008; Koehler et al., 2016; Papageorgiou et al., 2017; Smith et al., 1995; Tam et al., 
2014). There were 281 and 216 participants in intervention and control groups, respectively. The mean 
duration of interventions was 20 weeks and the mean age of participant was 36 years old. All studies were 
randomized controlled clinical trials and three studies described a cross-over design (Koehler et al., 2016; 
Papageorgiou et al., 2017; Smith et al., 1995). Headache and weakness were minore adverse effects reported 
as a result of  of intervention. 
3.2. Meta-analysis results 
Ten studies containing eleven arms providing a total of 472 participants reported changes in IGF-1 plasma 
levels as an outcome measure. Combined results using the random-effects model showed an overall 
insignificant reduction in IGF-1 following fasting or energy restricting (WMD: -16.41 ng/ml, 95% CI: -
35.88, 3.07; Fig 1.). There was, however, a significant degree of heterogeneity among studies (p=0.001, 
I2=90%). 
3.3. Subgroup analysis 
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We subsequently stratified studies based on intervention type (Table 2). These analyses showed that fasting 
regimens (WMD: -28.87 ng/ml, 95% CI: -43.69, -14.05, I2=00%) more effectively reduced IGF-1 than 
energy restricting regimens (WMD: -10.98 ng/ml, 95% CI: -33.08, 11.11, I2=90%). However, a significant 
heterogeneity among energy restricting studies was also noted. In order to identify the source of this 
heterogeneity we, therefore, sub-grouped energy restricted studies based on percent of daily energy intake: 
those limiting to ≤50% normal required daily energy intake and those with limits >50% normal required 
daily energy intake (Fig. 2). This analysis demonstrated that energy restriction significantly reduced IGF-1 
levels when the energy intake is limited to 50% or less of normal required daily energy intake (WMD: -
36.57 ng/ml, 95% CI: -59.19, -13.95, I2=00%).  
3.4. Dose-response and meta regression 
Seven studies containing eight arms demonstrated relation between energy restriction and changes in IGF-
1 plasma levels (Barnosky et al., 2017; Fontana et al., 2016; Fontana et al., 2008; Koehler et al., 2016; 
Papageorgiou et al., 2017; Smith et al., 1995; Tam et al., 2014). Subsequent analysis of the relationship 
between percentage of recommended daily energy intake and plasma IGF-1 alterations revealed a positive 
correlation (Coefficient for dose-response analysis=1.0533, P for meta regression=0.04; Fig.3). That is to 
say that the more substantial the calorie restriction, the greater the degree of circulating IGF-1 depletion.  
3.5. Quality assessment  
Table 3 show tThe results of the quality assessment of included studies is displayed in Table 3, where it 
was concluded that m. Most studies had a high risk for bias.. The r Risk of bias originateds from the design 
of included studies; however, . Sincegiven the intervention of included studies was an energy restriction or 
fasting, studies could not reduce performance and detection bias, s. So, the likelihood results were adversely 
impacted is low.probability of the effect of these bas on the results may be low. 
 
3.6. Publication bias and sensitivity analysis 
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The Begg tests did not demonstrate significant publication bias between studies (p=0.45), although Egger’s 
test did report a significant publication bias between studies (p=0.01) and asymmetry in the funnel plot is 
observed (Supplemental Fig. 2). We applied the ‘trim and fill’ method for adjusting for publication bias 
(Supplemental Table 2). The results of sensitivity analysis did not show any significant differences beyond 
the limits of 95% CI of calculated SESs for fasting or energy restricting intervention studies on IGF-1 
(Supplemental Fig 3). 
3.7. Epidemiological cohort study 
The study population contained 3,394 participants (1,496 men and 1,898 women). Mean age of participants 
was 45 ± 17 years. Male and female participants with lower energy intake had significantly lower IGF-1 
levels when compared to those with high daily energy intake (p<0.001 and p<0.001, respectively; Fig. 4). 
 
4. DISCUSSION 
Despite promising preclinical experimental evidence and clinical associations, the efficacy with which 
fasting or energy restriction protocols alter age-related health in humans remains contentious, and reliable 
clinical evidence has not been the subject of systematic scrutiny up to this point. For this reason, the current 
meta-analysis aimed to compile and interrogate the currently available data surrounding the effects of such 
regimens on plasma levels of IGF-1 in humans. In this study, we reviewed a total of ten RCTs containing 
11 relevant arms: eight energy restriction and three fasting-type protocols. Overall, our research indicates 
that there was no effect of fasting regimens and energy restriction protocols when all arms were pooled. 
However, due to the significant degree of heterogeneity in this analysis, subgroup investigations were 
performed. The results demonstrate that fasting regimens and energy restriction protocols in which 
participants were limited to less than half of their required daily intake both resulted in significantly reduced 
levels of circulating IGF-1. 
Fasting and energy restriction-based dieting has garnered significant attention in the past decade 
for purported beneficial effects on metabolic function and age-related parameters. In parallel, a number of 
epidemiological studies have identified associations between elevated circulating IGF-1 and aging or cancer 
progression (Cao et al., 2015; Kaaks et al., 2000; Renehan et al., 2004; Sugumar et al., 2004; Travis et al., 
2016). For example, increased rates of gastrointestinal cancers are observed in acromegalic patients 
(Renehan et al., 2003), a cohort defined by inherently elevated levels of GH and IGF-1. In direct contrast, 
those individuals with hereditary IGF-1 deficiencies appear to enjoy vast protection from age-related 
cancers and diabetes (Guevara-Aguirre et al., 2011). In concert with this observational data, preclinical 
studies investigating the development of a plethora of age-related diseases (i.e., cancers, diabetes, 
cardiovascular and neurodegenerative diseases) have repeatedly demonstrated a role of IGF-1 (Harvie et 
al., 2011). For example, a recent study of calorie restriction in non-human primates demonstrated a 
significant improvement in longevity and reduction in age-related disease (Mattison et al., 2017). In 
addition, extensive meta-analysis of 59 preclinical studies examining the effect of calorie restriction 
regimens on cancer development also reported a staggeringly reduced tumour incidence odds ratio of 0.20 
across the models; although the propensity for intermittent fasting to achieve the same effect was deemed 
doubtful (Lv et al., 2014). The exact mechanisms through which fasting and energy restriction affect age-
related disease remain incompletely elucidated; however, IGF-1 may play an important role in age-related 
disease (Castellino et al., 2018; Junnila et al., 2013; Lechler et al., 2017; Longo, 2019; Mattson et al., 2004) 
and could represent a novel target in the combatting such disorders. 
The three studies assessing fasting-style regimens ultimately included in the present meta-analysis 
demonstrate a clear depletive effect of such protocols on circulating IGF-1, with little obvious heterogeneity 
between the study outcomes. However, the manner in which these studies were designed and executed 
differs somewhat. While two trials implemented an intermittent fasting regimen (Kessler et al., 2018; Moro 
et al., 2016), and the final study examined the effects of a ‘fasting-mimicking’ diet in which participants 
consumed a modified diet depleted in calories, carbohydrates and protein, but high in unsaturated fats (Wei 
et al., 2017). Although there is obvious discordance in the design of the latter study in relation to the two 
intermittent fasting studies, the positive effects certainly warrant further investigation and should be 
considered carefully. 
The CALERIE-1 trial, in which participants undertook a continuous 25% reduction in energy intake 
for six months, found that subjects reduced their 10-year cardiovascular risk by a substantial 10% 
(Heilbronn et al., 2006; Lefevre et al., 2009; Redman et al., 2010). Despite this, no effect on circulating 
IGF-1 was recorded. The same can be said for the CALERIE-2 trial, in which an extended 2-year 
intervention of the same energy restriction regimen brought about a range of biophysical and biochemical 
alterations, including a rise in IGFBP-1, yet failed to yield reductions in circulating IGF-1 levels (Fontana 
et al., 2016). This has previously been attributed to the young age and healthy status of the study participants 
(Most et al., 2017); however, the analysis presented herein in the present study indicates that calories 
restriction of less than 50% is ineffective in reducing IGF-1. Furthermore,Moreover we also demonstrate 
that IGF-1 alterations were dose-dependent in terms of response to percentage of daily energy intake 
restriction. In line with this, quartile grouping of men and women by their daily energy intake revealed 
significant trends, with the lowest energy intake quartiles demonstrating the lowest circulating IGF-1 levels 
in both men and women. With this in mind, future research may need to focus efforts and resources towards 
protocols with higher degrees of energy restriction, if we are to achieve IGF-1 depletion mediated effects.  
Finally, although not directly assessed in the present analysis, it is worth considering that 
intervention duration may have a paradoxical effect on IGF-1 levels. That is to say that the human system 
may adapt to extended periods (i.e. years) of calorie restriction, resulting in insignificantly altered levels of 
plasma IGF-1. This was exemplified by Fontana and colleagues, as they demonstrated that a short-term 3-
week calorie restriction, but not the extended 1 and 6-year interventions conferred a significant decrease in 
circulating IGF-1 (Fontana et al., 2008). In line with this, three of the arms analysed in this meta-analysis 
with the longest intervention durations were not found to display significantly reduced IGF-1 at study 
completion (Barnosky et al., 2017; Fontana et al., 2016; Tam et al., 2014). Therefore, we must ask the 
question: does the short-term effect of such regimens on IGF-1 concentration persist over time? This may 
be an important consideration for future research and should encourage trials to monitor IGF-1 in a kinetic 
manner over the course of intervention. 
Limitations and strengths 
There are several limitations of this study which are important to consider. The studies included in this 
meta-analysis all contained small and relatively heterogenous RCTs (n=6-188), and just three studies 
assessed fasting-style regimens. In addition, there existed a substantial degree of heterogeneity in 
experimental design between studies, with a wide range of intervention durations and dietary intervention 
protocols. Finally, the studies included reported on a range of subject types, including obese, overweight 
and healthy-weight adults. It should be considered that these populations likely display differing levels of 
plasma IGF-1, although this issue is partially controlled for by considering alterations from baseline. In 
addition, despite these heterogeneities, the random-effects model methodology applied to the current study 
represents a significant design strength in further controlling for such factors. Interestingly, despite the high 
level of calorie restriction applied in the included studies, there were no major adverse events reported. 
Although, in some trials, authors reported a minimal number of participants lost to attrition, and  attributed 
to; dissatisfaction with study diets, scheduling conflicts, and personal reasons. in Table 1 we demonstrate 
that only two studies reported adverse effects attributable to intervention. In Kessler et al (2018), headache, 
migraine, nausea, ravenousness, circulatory disturbance, hunger, general feeling of weakness, tiredness, 
stomach ache, meteorism, heartburn, and cold sensations in the body. Similarly, in Wei et al (2016), fatigue, 
weakness, and headaches were reported. Moreover, two studies, Barnosky et al (2017) and Fontana et al 
(2016), reported that 11 and 26 intervention group participants were lost to attrition, respectively; however, 
there were no adverse issues or events reported. In fact, in all included studies in this meta-analysis, the 
intervention was regarded as being safe. PromisinglyMoreover, in some studies, for example, Brandhorst 
et al (2015), a systematic evaluations of tolerability and perceived adverse events was have been conducted; 
where only mild discomfort was reported, and most occurrent in the initial stages of prolonged 
fasting/calorie restriction, after which, participant reported adversity was lower, which could explain why 
Barnosky et al (2017) and Fontana et al (2016) had participants withdraw, but had no adverse events 
reported. Notwithstanding, however, caution must be taken with respect to the population/patient enrolled 
on such an extreme calorie restriction (50%), which could cause adverse effects, including the exacerbation 
of previous malnourishments and dysfunctions, particularly in old and frail participants. Thus, highlighting 
the need for detailed viability assessment and patient history documentation prior to enrolment on any 
fasting or calorie restricting diet. A further, potential limitation, and indeed avenue for further work, is that, 
due to a dearth of eligible studies, we could not evaluate macronutrient composition of diets, which may 
conceivably be of importance. It is possible that, independent of calories, a protein or carbohydrate 
restriction may have a different effect on IGF-1. For instance, it is recognized that protein deprivation is 
associated with lower IGF-1 concentrations in animals and malnourished children (Estívariz and Ziegler, 
1997; Thissen et al., 1994; Underwood et al., 1994); whilst in healthy well-nourished men, greater dietary 
intake of protein is shown to be associated with higher IGF-1 concentrations (Larsson et al., 2005). On the 
other hand, intakes of total energy, alcohol, total fat, and carbohydrate are reportedly not associated with 
IGF-1 concentrations (Larsson et al., 2005). Thus, the authors advocate that further research manipulate 
and assess the composition and restriction of dietary macronutrients, and the subsequent impact of IGF-1. 
 
5. CONCLUSIONS 
The primary outcome of this study was that, when compiled together, RCT studies assessing fasting and 
energy restricting diets did not demonstrate elicit a significant effect on circulating IGF-1. However, 
subsequent subgroup analyses revealed that both fasting regimens and energy restriction to ≤50% normal 
required daily energy intake resulted in significantly reduced levels of plasma IGF-1 in humans subjects. 
These results suggest that, although there is significant variability in the efficacy of different protocols, 
such regimens may be efficacious when designed in the appropriate manner. Future confirmatory studies 
should investigate energy restriction protocols of 50% or greater, and their efficacy and adherence, in order 
to explore whether reduction in IGF-1 is associated with clinically-relevant improvements metabolic and 
age-related parameters for humans; however, given the extreme level of fasting required to elicit an effect, 
this must be approached with caution and with careful consideration of the target population. TFinally, to 
the authors’ knowledge, this study represents the first meta-analysis to investigate the effects of fasting and 
energy restricting regimens on circulating IGF-1 and should aid in directing future research in the area.. 
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